Good salary, nice bonus — but why did biotech mogul David Hung gamble on Axovant?
The biotech’s stock ended up 23% as investors cheered the return of the legendary biotech dealmaker, not so long after his crowning achievement: A $14 billion buyout for Medivation.
That boost added $340 million to the market cap, which Axovant’s Vivek Ramaswamy — one of the savviest players to ever make the leap from hedge fund to biotech — immediately sought to cash in on with a $100 million shelf offering.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.